Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | MGMT | P16455 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 3/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1221824 | 0.94 | MRGPRX4 (0.36) | BRD4PIK3CGMGMTMCHR1ALDH1A1 | |
| SCHEMBL2817380 | 0.92 | ALKBH1 (0.38) | BRD4PIK3CGMCHR1ALDH1A1TSHR | |
| SCHEMBL369345 | 0.90 | MRGPRX4 (0.43) | SMN1; SMN2ALDH1A1TSHRMAPK1HSD17B10 | |
| SCHEMBL1221006 | 0.89 | HSD17B10 (0.35) | BRD4PIK3CGMCHR1ALDH1A1TSHR | |
| SCHEMBL12894204 | 0.87 | KDM4E (0.36) | GAASMN1; SMN2PIK3CGALDH1A1HSD17B10 | |
| SCHEMBL12894060 | 0.81 | KDM4E (0.38) | SMN1; SMN2PIK3CGALDH1A1HSD17B10ALOX15 | |
| SCHEMBL1221211 | 0.81 | MYC (0.34) | GAAPIK3CGALDH1A1TSHRHSD17B10 | |
| SCHEMBL13512873 | 0.80 | KDM4E (0.34) | SMN1; SMN2PIK3CGALDH1A1HSD17B10ALOX15 | |
| SCHEMBL368141 | 0.80 | MRGPRX4 (0.42) | GAASMN1; SMN2ALDH1A1TSHRMAPK1 | |
| SCHEMBL368771 | 0.80 | LMNA (0.35) | GAAMCHR1ALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2759544-A1 | Compounds having antiviral properties | Avexa Limited (AU) | 2014-07-30 | — | — | EP | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
| US-8318732-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2012-11-27 | — | — | US | disclosed |
| US-8318732-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2012-11-27 | — | — | US | disclosed |
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2011-02-17 | — | — | US | disclosed |
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2011-02-17 | — | — | US | disclosed |
| EP-2212324-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | Avexa Limited (AU) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010000032-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | ZC3HAV1, ACE, EIF2AK2 | GAA 30/4885SMN1; SMN2 903/4885BRD4 3765/4885 |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | ZC3HAV1, ACE, EIF2AK2 | GAA 30/4885SMN1; SMN2 903/4885BRD4 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.